FDA Clears GE’s Cardiac Spectral CT

Article

GE Healthcare’s cardiac spectral CT has received FDA 510(k) clearance, the company announced.

GE Healthcare’s cardiac spectral CT has received FDA 510(k) clearance, the company announced. The Discovery CT750 HD Freedom Edition addresses challenges in cardiac imaging such as coronary motion, calcium booming, plaque composition and accurate myocardial perfusion, the company said.

The system provides the following features: Motion Freedom with motion correction via SnapShot Freeze, which helps reduce cardiac motion by detecting vessel motion and velocity to determine the position and correct the effects of motion; Calcium Freedom with enhanced coronary visualization using Gemstone Spectra Imaging Cardiac; and Horizon Free, which provides plaque material composition assessment and accurate perfusion calculations.

The HD Freedom Edition’s first U.S. installation was at the University of Washington, Seattle, and is available in about two dozen locations in Europe and Japan, where physicians are using SnapShot Freeze and GSI Cardiac in routine practice for coronary evaluation.

According to GE, the system leads the industry in cardiac CT spatial resolution at 18.2 lp/cm, which helps physicians accurately quantify stenoses in coronary vessels by displaying reduction in calcium blooming compared to standard resolution.

Recent Videos
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Related Content
© 2025 MJH Life Sciences

All rights reserved.